Vertex Pharma Stock-Based Compensation — Historical Data
Vertex Pharma (VRTX) stock-based compensation was $686M in FY2025 (-2% YoY). The tables below show the complete quarterly and annual stock-based compensation history, sourced from SEC EDGAR 10-K and 10-Q filings.
Annual Stock-Based Compensation
Fiscal Year
Stock-Based Compensation
YoY
2025
$686M
-2%
2024
$698M
+20%
2023
$581M
+18%
2022
$491M
+11%
2021
$441M
+3%
2020
$430M
+19%
2019
$360M
+11%
2018
$325M
+11%
2017
$293M
+22%
2016
$241M
+4%
2015
$231M
+30%
2014
$178M
+40%
2013
$127M
+11%
2012
$114M
-4%
2011
$118M
+30%
2010
$91M
+5%
2009
$87M
+50%
2008
$58M
Recent Quarterly Stock-Based Compensation
Quarter
Stock-Based Compensation
Q1 2026
$166M
Q4 2025
$158M
Q3 2025
$195M
Q2 2025
$167M
Q1 2025
$166M
Q4 2024
$168M
Q3 2024
$185M
Q2 2024
$154M
Q1 2024
$192M
Q4 2023
$209M
Q3 2023
$131M
Q2 2023
$119M
Source: VRTX on EDGAR. Data from SEC EDGAR 10-K and 10-Q filings. Updated quarterly.